PVCT Provectus Biopharmaceuticals - Correlation between Tumor Mutational Burden and Objective Response Rate with Anti–PD-1 or Anti-PD–L - PVCT Provectus Biopharmaceuticals - InvestorVillage
PVCT Provectus Biopharmaceuticals

  • Investor Village needs your help. We are working hard to improve your user experience
    by upgrading the site so it works better on the latest mobile devices, browsers, O/S, etc. Because costs exceed our normal operating budget, we are asking everyone, including "lurkers," to support our efforts.

    Click this PayPal link to make a one-time contribution in whatever amount you think is fair.

    Or click here to support us with a monthly contribution, starting as low as $2.50 per month.

    Payments can be made directly via PayPal or Credit Card with no need to create an Investor Village account. Cancel any time.

This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: PVCT Provectus Biopharmaceuticals   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  4318 of 4716  at  7/11/2019 10:45:45 AM  by

PVCTismyBMW


 In response to msg 4317 by  Hombre77
view thread

Re: Correlation between Tumor Mutational Burden and Objective Response Rate with Anti–PD-1 or Anti-PD–L1 Therapy in 27 Tumor Types

 Hombre:  This stock simply doesn't fit in a scenario where we can discuss buyout offers at some premium to current share price.  Nobody on this board feels the $0.07/share price today reflects fair market value.  I promise you that PRH do not think $0.07 reflects anything close to fair value.  
 
In order for someone to buy this company at $0.35/share, they would have to successfully get through a proxy at that price.  I own a lot of shares.  My vote on a $0.35/share sale is a very quick no.  My vote on a $0.70/share buyout is very quick no.  My vote on a $3.50/share buyout, 10x your example...hmmm, interesting, let me think about that for a minute (likely yes).   
 
I believe a $0.35/share buyout offer would get yes votes from all the Maxim rachet shareholders, but few others.  It would be hostile, unsupported by the Board (in my uninformed opinion).   


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 8     Views: 208
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
4319 Re: Correlation between Tumor Mutational Burden and Objective Response Rate with Anti–PD-1 or Anti-PD–L1 Therapy in 27 Tumor Types Hombre77 0 7/11/2019 11:21:57 AM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...